Literature DB >> 1716088

Antiretroviral activities of anthraquinones and their inhibitory effects on reverse transcriptase.

H Higuchi1, K Mori, A Kato, T Ohkuma, T Endo, H Kaji, A Kaji.   

Abstract

Alizarin complexone (AC), alizarin Red S (ARS) and various other anthraquinones were evaluated for their inhibitory effects on Rous-associated virus 2 reverse transcriptase (RAV-2 RT). Some 1,2-dihydroxyanthraquinones were active against this enzyme and AC was the most potent inhibitor among these compounds [50% inhibitory concentration (IC50): 3.8 micrograms/ml]. AC slightly inhibited Rous sarcoma virus RT (RSV RT) and human immunodeficiency virus type 1 RT (HIV-1 RT) (IC50: 100 micrograms/ml and 45 micrograms/ml, respectively). However, AC efficiently inhibited focus formation by Rous sarcoma virus (RSV) and cytopathogenicity of human immunodeficiency virus type 1 (HIV-1). Simultaneous administration of AC with RSV to newborn chickens also delayed tumor induction by RSV.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716088     DOI: 10.1016/0166-3542(91)90067-2

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  7 in total

1.  Inhibition of HIV-1 reverse transcriptase by aryl-substituted naphto- and anthraquinones.

Authors:  T V Ilina; E A Semenova; T R Pronyaeva; A G Pokrovskii; I V Nechepurenko; E E Shults; O I Andreeva; S N Kochetkov; G A Tolstikov
Journal:  Dokl Biochem Biophys       Date:  2002 Jan-Feb       Impact factor: 0.788

2.  Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules.

Authors:  C M Farnet; B Wang; J R Lipford; F D Bushman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

3.  Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases.

Authors:  Francesca Esposito; Tatyana Kharlamova; Simona Distinto; Luca Zinzula; Yung-Chi Cheng; Ginger Dutschman; Giovanni Floris; Patrick Markt; Angela Corona; Enzo Tramontano
Journal:  FEBS J       Date:  2011-03-16       Impact factor: 5.542

4.  Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism.

Authors:  C M Farnet; B Wang; M Hansen; J R Lipford; L Zalkow; W E Robinson; J Siegel; F Bushman
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase.

Authors:  T Fujihashi; H Hara; T Sakata; K Mori; H Higuchi; A Tanaka; H Kaji; A Kaji
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

6.  Anti-cytomegalovirus activity of the anthraquinone atanyl blue PRL.

Authors:  Zohaib Alam; Zainab Al-Mahdi; Yali Zhu; Zachary McKee; Deborah S Parris; Hardik I Parikh; Glen E Kellogg; Alison Kuchta; Michael A McVoy
Journal:  Antiviral Res       Date:  2014-12-10       Impact factor: 5.970

7.  The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation.

Authors:  Giorgio Cozza; Andrea Venerando; Stefania Sarno; Lorenzo A Pinna
Journal:  Biomed Res Int       Date:  2015-10-19       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.